Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/30030
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18074/20272 (89%)
造訪人次 : 4156887      線上人數 : 6178
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/30030


    標題: 利用實驗設計法進行難溶性藥物Ezetimibe之錠劑研究
    Formulation studies of poor drug Ezetimibe tablet using experimental design
    作者: 陳俊琪
    貢獻者: 藥學系
    宋國峻
    劉國盛
    關鍵字: Croscamellose
    粒徑大小
    田口氏直交表
    Ezetimibe
    實驗設計法
    Polyvinylpyrrolidonek30
    Particle size
    Orthogonal Arrays
    Ezetimibe
    Experimental design
    Croscamellose
    Polyvinylpyrrolidonek30
    日期: 2016
    上傳時間: 2016-12-21 15:31:55 (UTC+8)
    摘要: 難溶藥物在?即釋放之劑型設計上,除了須考慮複雜的處方設計外,尚須使用適當的製程??,為達處方設計之最佳化,所以需要控制的變因種?則?多,本研究則?用實驗設計法(Experimental Design),進而達到處方設計之最佳化。在處方設計上主要探討活性成分的粉末顆?大小、黏合劑Polyvinylpyrrolidonek30(PVP k30)的配方含?及崩散劑Croscamellose(CROS)的配方含?等三個因子,製劑設計乃以乾式造粒法的方式?使其活性成份分散均勻,使藥物在預定的時間內?達到完全的釋放與溶解。實驗設計法之方式為田口氏直交表(Orthogonal Arrays)。採用直交表L9(34)的方式,以三個因子各以三個水準?設計處方。經過實驗得知,影響藥物溶?最大之因子為活性成分的崩散劑CROS,其次為Particle Size,而黏合劑PVP k30對溶離結果在統計上沒有影響。最後再利用此依據再做調整達到處方的最佳化,而實驗溶?結果與預定之溶?目標以f 2值比對,得到第二個處方(L2)為最適化處方:處方中活性成分顆?大小為0.1-2.8μm、CROS配方百分比含?為2%、PVP k30配方百分比含?為4%。
    When designed the content of formulation excipients, process of manufacture shoild be considered, therefore many factors need to be considered to design a formulation. This study used experimental design to assess the main factor of dissolution and perform dissolution studies.  There are three factors to be discussed in this study, they are, Particle size of API, content of Binder and content of Disintegrant. Process of manufacture is based on blending technique, and dry granulation method (one of dispersion technique) to homogenize API and make sure drug to dissolve and release completely in the short time.  There are several steps in experimental design. Experimental design is performed on formulation by Taguchi Method (Orthogonal Arrays: L9(3)4)(4 factors, 3 levels).   After experiment, second formulation(L2) found to be the optimizing formulation, the optimal formulation is particle size of API: 0.1-2.8μm, binder: 2%, disintegrant: 4%. There showed thatthe content of disintegrant is main effect in this study, the second factor is particle size of API, binder content has the smallest influence on tablet dissolution.
    關聯: 網際網路公開:2021-08-19,學年度:104,73頁
    顯示於類別:[藥學系(所)] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML436檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋